Why Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Down 12.14%
As of Tuesday, July 28, Atea Pharmaceuticals, Inc.’s AVIR share price has dipped by 12.14%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Down 20.12%
As of Tuesday, July 28, Atea Pharmaceuticals, Inc.’s AVIR share price has dipped by 20.12%, which has investors questioning if this is right time to buy.Tudor Pop
Why Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Up 5.70%
As of Thursday, June 04, Atea Pharmaceuticals, Inc.’s AVIR share price has surged by 5.70%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Down 5.47%
As of Thursday, May 14, Atea Pharmaceuticals, Inc.’s AVIR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Michael Rose
Why Atea Pharmaceuticals, Inc.’s (AVIR) Stock Is Down 7.91%
As of Wednesday, May 13, Atea Pharmaceuticals, Inc.’s AVIR share price has dipped by 7.91%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | AVIR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $379.3 | $569.9 | 34% |
|
| Shares Out (Mil) | 79.2 | 44.8 | 58% |
|
| Institutional Ownership | 80.8% | 84.6% | 50% |
|
| Float (Mil) | 60.1 | 45.1 | 52% |
|
| Beta | 0.38 | 0.67 | 21% |
|
| Avg Daily Volume (000s) | 438 | 294 | 57% |
|
| Price Change (52-week) |
24.7% | 65.2% | 66% |
|
| Growth | AVIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (70.8%) | (2.0%) | 4% |
|
| EPS (5yr) | (30.7%) | 14.9% | 8 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (60.3%) | (14.9%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.555) | ($1.925) | ($1.385) | |
| Month Ago EPS | ($0.555) | ($1.925) | ($1.385) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.565) | ($1.930) | ($1.385) | |
| Year/Year Chg | (3.3%) | (0.9%) | (51.1%) | |
| Financials | AVIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($170) | ($11) | 7% |
|
| EPS (TTM) | ($2.119) | ($0.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($148) | ($6) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($40) | $4 | 21% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $110 | $493 | 22% |
|
| Valuation | AVIR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.62 | 2.89 | 43% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AVIR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (48.0%) | (25.5%) | 12% |
|
| ROE | (52.6%) | (21.4%) | 15% |
|
| Liabilities to Assets | 12.5% | 35.5% | 7% |
|
| F-Score | 3 | 3 | 19% |
|
Atea Pharmaceuticals, Inc. did not pass any screens on 7/30/2026.
